Adeka (4401) Q1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 earnings summary
23 Oct, 2026Executive summary
Q1 FY2023 net sales fell JPY 7.1B YoY to JPY 94.5B; operating profit declined JPY 1.6B to JPY 7.4B.document-source0
Lower sales volume outweighed positive net pricing and foreign-exchange effects; the chemicals segment faced the most challenging conditions.document-source1
Financial highlights
Current profit declined JPY 2.2B YoY to JPY 8.1B; profit attributable to owners of parent fell JPY 1.0B to JPY 5.1B.document-source0
EPS decreased JPY 9.6 YoY to JPY 50.document-source0
Outlook and guidance
FY2023 sales forecast remains JPY 426B; H1 was revised from JPY 202B to JPY 191B, with H2 raised from JPY 224B to JPY 235B.document-source7
FY2023 operating profit forecast remains JPY 36B; H1 forecast is JPY 13.3B and H2 JPY 22.7B.document-source8
FY2023 current profit forecast is JPY 35.5B and profit attributable to owners of parent JPY 21B; H1 forecasts were lowered and H2 forecasts raised.document-source8
Food products' operating profit forecast increased JPY 600M for FY2023, with forecasts raised slightly in both halves.document-source9
Latest events from Adeka
- Record FY2023 profits set the stage for ADX 2026 growth and JPY 75 billion in CapEx.4401
Q4 2024 - Pricing and FX cushioned volume-led pressure as FY2023 guidance remained unchanged.4401
Q3 2024 - Strong sales and profit growth led by chemicals and semiconductors; outlook and dividends raised.4401
Q1 2027 - Record FY2025 results; FY2026 forecasts further growth but exclude Middle East impacts.4401
Q4 2026 - H1 growth lifted FY2024 guidance and dividends, led by Chemicals.4401
Q2 2025 - Nine-month profit rose 25.1%, led by Chemicals, as semiconductor investment advanced.4401
Q3 2025 - Record FY2024 results, with FY2025 growth forecast amid tariff and cost risks.4401
Q4 2025 - Profit and sales rose, led by Life Science, with stable outlook and higher dividend forecast.4401
Q1 2026 - Profit rose on strong Life Science and Environmental Materials, offsetting Chemicals weakness.4401
Q3 2026